Jagdev Singh Sekhon

1.4k total citations
6 papers, 501 citations indexed

About

Jagdev Singh Sekhon is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jagdev Singh Sekhon has authored 6 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Surgery and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jagdev Singh Sekhon's work include Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Jagdev Singh Sekhon is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Jagdev Singh Sekhon collaborates with scholars based in India, Spain and United States. Jagdev Singh Sekhon's co-authors include Shona Nag, Allen S. Melemed, Joyce O’Shaughnessy, A Płużańska, G. Calderillo-Ruiz, Janusz Rolski, Lorinda Simms, Kathy S. Albain, Antonio Llombart‐Cussac and Sunil K. Gupta and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Seminars in Oncology.

In The Last Decade

Jagdev Singh Sekhon

5 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jagdev Singh Sekhon India 5 346 164 123 119 75 6 501
Karin Rita Tamas Switzerland 5 493 1.4× 162 1.0× 210 1.7× 97 0.8× 64 0.9× 5 554
Miwa Nishida Japan 6 322 0.9× 93 0.6× 106 0.9× 69 0.6× 156 2.1× 7 469
Domenico Priolo Italy 6 169 0.5× 59 0.4× 52 0.4× 97 0.8× 92 1.2× 9 364
Hiral D. Parekh United States 10 243 0.7× 102 0.6× 56 0.5× 117 1.0× 81 1.1× 30 409
Yiqun Han China 12 369 1.1× 133 0.8× 116 0.9× 22 0.2× 120 1.6× 43 576
Ondřej Kubeček Czechia 8 171 0.5× 101 0.6× 46 0.4× 62 0.5× 60 0.8× 31 339
Corey Carter United States 11 161 0.5× 144 0.9× 69 0.6× 84 0.7× 147 2.0× 24 417
Kakil Ibrahim Rasul Qatar 9 192 0.6× 116 0.7× 122 1.0× 63 0.5× 183 2.4× 48 495
Miaozun Zhang China 14 204 0.6× 180 1.1× 120 1.0× 159 1.3× 198 2.6× 29 520
Baha Zengel Türkiye 9 180 0.5× 73 0.4× 190 1.5× 76 0.6× 111 1.5× 44 426

Countries citing papers authored by Jagdev Singh Sekhon

Since Specialization
Citations

This map shows the geographic impact of Jagdev Singh Sekhon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jagdev Singh Sekhon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jagdev Singh Sekhon more than expected).

Fields of papers citing papers by Jagdev Singh Sekhon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jagdev Singh Sekhon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jagdev Singh Sekhon. The network helps show where Jagdev Singh Sekhon may publish in the future.

Co-authorship network of co-authors of Jagdev Singh Sekhon

This figure shows the co-authorship network connecting the top 25 collaborators of Jagdev Singh Sekhon. A scholar is included among the top collaborators of Jagdev Singh Sekhon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jagdev Singh Sekhon. Jagdev Singh Sekhon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Ranade, Anantbhushan, P. P. Bapsy, Shona Nag, et al.. (2012). A multicenter phase II randomized study of Cremophor‐free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline. Asia-Pacific Journal of Clinical Oncology. 9(2). 176–181. 15 indexed citations
2.
Parikh, Purvish M., Ashok K. Vaid, Suresh H. Advani, et al.. (2011). Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy. Journal of Clinical Oncology. 29(31). 4129–4136. 62 indexed citations
3.
Albain, Kathy S., Shona Nag, G. Calderillo-Ruiz, et al.. (2008). Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment. Journal of Clinical Oncology. 26(24). 3950–3957. 316 indexed citations
4.
Sekhon, Jagdev Singh, et al.. (2007). Multiple Myeloma Presenting with Hepatic Involvement. Indian Journal of Medical and Paediatric Oncology. 28(3). 41–43.
5.
Doval, Dinesh Chandra, Jagdev Singh Sekhon, Sunil K. Gupta, et al.. (2004). A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. British Journal of Cancer. 90(8). 1516–1520. 104 indexed citations
6.
Doval, Dinesh Chandra, et al.. (2002). Chemotherapy in biliary tract carcinomas: Results in India. Seminars in Oncology. 29(6U). 46–50. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026